论文部分内容阅读
目的探讨TP方案在小细胞肺癌(SCLC)治疗中的应用价值。方法1996年5月至2004年10月收治的69例SCLC患者,随机分为TP组和EP组两组,分别为35例和34例。TP组:Taxol135mg/m2,d1,ivdrip;DDP80～100mg/m2,d2,ivdrip。EP组:VP-16100mg/m2,d1～3,ivdrip;DDP80mg/m2,d1,ivdrip。观察比较两组的疗效及不良反应。结果TP组完全缓解(CR)8例(22.86%),部分缓解(PR)19例(54.29%),稳定(SD)6例(17.14%),进展(PD)2例(5.71%),有效(CR+PR)率为77.14%。EP组CR9例(26.47%),PR18例(52.94%),SD5例(14.71%),PD2例(5.88%),有效率为79.41%。两组有效率比较差异无显著性(P>0.05)。骨髓抑制和脱发发生率较高,但两组之间无显著性差异(P>0.05)。过敏反应、肌肉关节疼痛、腹泻发生于TP组,多为Ⅰ°～Ⅱ°,通过对症治疗可耐受,不影响治疗。无超敏反应。结论TP方案与最常用的EP方案相比,疗效相似,虽有一些毒副作用,但较轻,病人能耐受,不影响治疗,可以作为一线方案推广应用。
Objective To investigate the value of TP regimen in the treatment of small cell lung cancer (SCLC). Methods Sixty-nine patients with SCLC who were treated between May 1996 and October 2004 were randomly divided into two groups: TP group and EP group, 35 cases and 34 cases respectively. TP group: Taxol135mg / m2, d1, ivdrip; DDP80 ~ 100mg / m2, d2, ivdrip. EP group: VP-16100mg / m2, d1 ~ 3, ivdrip; DDP80mg / m2, d1, ivdrip. The curative effects and adverse reactions of the two groups were observed and compared. Results There were 8 cases (22.86%) of complete remission (CR), 19 cases (54.29%) of partial remission (PR), 6 cases of stable (SD) and 17 cases of progressive (PD) (CR + PR) rate of 77.14%. In EP group, 9 cases (26.47%) were CR, 18 cases (52.94%) were PR, 14 cases were SD (14 cases) and 2 cases were PD (5.88%). The effective rate was 79.41%. There was no significant difference between the two groups (P> 0.05). The incidence of bone marrow suppression and alopecia was higher, but there was no significant difference between the two groups (P> 0.05). Allergic reactions, muscle and joint pain, diarrhea occurred in the TP group, mostly Ⅰ ° ~ Ⅱ °, can be tolerated through symptomatic treatment, does not affect the treatment. No hypersensitivity. Conclusion Compared with the most commonly used EP regimen, TP regimen has similar curative effect. Although it has some toxic and side effects, the TP regimen is lighter and the patient can tolerate without affecting the treatment and can be used as a first-line plan.